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intra-tumor genetic heterogeneity, has long been suspected of playing a role in poor responses
to therapy. Research over the past decade has documented the existence of such heterogene-
ity within tumors of individual patients and documented its potential clinical significance. The
research methods for identifying this heterogeneity were not, however, readily adaptable to
widespread clinical application. After a brief review of this background, we describe the devel-
opment of a measure of intra-tumor genetic heterogeneity, based on whole-exome sequencing
of individual tumor samples, that could be applied to biopsy specimens in a clinical setting.
This measure has now been used in head and neck squamous cell carcinoma (HNSCC) to docu-
ment, for the first time, a relation of high intra-tumor genetic heterogeneity to shorter overall
survival in a large, multi-institutional study. The implications of heterogeneity for research and
clinical care thus now need to be addressed.
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The genetic progression model of head and neck squamous
cell carcinoma (HNSCC),1 now twenty years old, assumed
an essentially linear progression from normal mucosa
through dysplasia and carcinoma in situ to invasive cancer.
That work also, however, recognized that neighboring cells
in or near a tumor could differ genetically. The authors
noted that their work provided “a possible mechanism for
field cancerization,” in that “early genetic events may be
shared by cells in a local anatomic area, which are appar-
ently derived from a common clone.” This model provided a
reasonable explanation for multiple primary tumors arising
from the same anatomic area in a patient, as “subsequent
genetic events in various subclones produce different
phenotypic alterations.”
A related type of genetic diversity, among the cancer
cells within an already invasive tumor, has recently been
found to be of great importance in HNSCC and other types
of cancer. Here we review how such intra-tumor genetic
heterogeneity has been found to be important in tumor
development and responses to therapy. We then discuss
some clinical implications of this heterogeneity, and a way
to evaluate this heterogeneity that can be translated from
research to the clinic.
Historical background
By intra-tumor genetic heterogeneity we mean the pres-
ence of differences in genomic DNA sequences among
cancer cells of an individual tumor, which can be passed
down to progeny as the cancer cells divide. These differ-
ences can include point mutations, copy-number alter-
ations (CNA), and intra- or inter-chromosomal
translocations.
The idea that cancer cells within a tumor might differ
genetically is not new. Concepts of intra-tumor heteroge-
neity and its implications for therapy date back at least to
the 1970s, as some results with early mouse models of
cancer were best explained if there were cells having
different sensitivities to cytotoxic therapy or different
tendencies to metastasize in the same tumor.2e4 Around
that time, low DNA replication fidelity in tumors was
identified as a potential mechanism for genetic differences
among cancer cells.5 Until a few years ago, however, little
attention was paid to such potential differences among
cancer cells within a tumor.
The frequent failures of targeted therapy recently
brought renewed attention to intra-tumor heterogeneity. A
drug designed to target the particular oncogene driving a
tumor was expected to provide a magic bullet that would
kill all the cancer cells depending on it.6 Although dramatic
initial responses to such drugs could be obtained, these
were almost always followed by relapse and tumor
regrowth.7 Intra-tumor heterogeneity, as proposed decades
previously, provided a reasonable explanation for such
initial success followed by treatment failure: therapy
selecting for pre-existing subclones that had mutated in
ways that happened to provide resistance.
This lack of detailed attention to intra-tumor hetero-
geneity until a few years ago may in part have been due to anecessary focus on fundamental cellular and molecular
mechanisms of cancer, before dealing with what might
have originally been considered second-order issues like
differences within a tumor. Perhaps more important,
however, there were few useful tools for examining such
heterogeneity until a few years ago.Sequencing methods and intra-tumor
heterogeneity
The most direct way to examine intra-tumor genetic
heterogeneity is to compare DNA sequences among regions
of a tumor. Until about 10 years ago, however, detailed
genomic DNA analysis was based on Sanger sequencing,
which had difficulty detecting even known variants present
in 10%e20% of a sample’s DNA,8 let alone quantifying un-
known variants at that level. In practice this posed a sig-
nificant problem for analyzing mutations present in tumor
subclones. For example, say that a heterozygous mutation
is present in a subclone representing 30% of the cancer
cells. Then even if there were no normal cells within the
tumor sample, the mutation (involving 15% of cancer-cell
DNA) would already be down near the Sanger-sequencing
detection limit. With many tumor samples containing
relatively large amounts of normal cells and their normal
DNA (called DNA “impurity” in the jargon of those who
study tumor mutations), it would have been difficult to
adapt Sanger sequencing to quantitative analysis of intra-
tumor genetic heterogeneity.
The usefulness of DNA sequencing for analyzing hetero-
geneity was dramatically enhanced by the adoption of
next-generation sequencing (NGS) for large-scale tumor
analysis. Besides dramatically reducing costs, NGS allows
better quantitation of individual mutations. In contrast to
the analog readout from Sanger sequencing, NGS analyzes
each (typically amplified) piece of DNA separately.9 Thus
the fraction of DNA bearing a particular mutation is simply
the fraction of DNA pieces covering a particular locus that
show the mutation, the “mutant-allele fraction” (MAF).
Increasing the sequencing depth, the number of DNA pieces
analyzed that cover the desired portion of the genome,
thus can allow detection of MAF down to levels of a few
percent.10 NGS can be combined with prior enrichment for
the protein-coding regions of the genome, called exome
sequencing, or with whole-genome amplification to allow
sequencing down to individual cells.Modern research measurements of
heterogeneity
The work of Maley et al11 on the progression of Barrett’s
epithelium to invasive esophageal adenocarcinoma may
mark the beginning of the recent resurgence of research on
the clinical importance of genetic heterogeneity in cancer.
Those authors compared several genetic markers (LOH and
microsatellite shifts at multiple genomic loci, and muta-
tions in TP53 and CDKN2A) among flow-purified fractions of
cells from multiple sites within individual patients’ Bar-
rett’s epithelia. Based on these results, they determined
differences in subclonal composition among the sites of
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the most clonal diversity were also the most likely to
progress to adenocarcinoma.
Genetic heterogeneity has been examined in several
types of tumors. For example, in breast cancer, differences
among cells were determined even down to the single cell
level, with CNA patterns analyzed by fluorescent in-situ
hybridization (FISH) of defined genomic regions12 or by
whole-genome sequencing of single cells.13 In addition to
identifying genetically distinct subclones within primary
tumors, it was shown that a single clone of an aneuploid
cell could seed a liver metastasis.13 Single-cell sequencing
also found genetic diversity in the form of “pseudodiploid”
cells with nonrecurring CNA patterns, presumably not
forming distinct clones.13 FISH was used to examine CNAs of
particular receptor tyrosine kinase (RTK) genes among
glioblastoma cells.14 Distressingly for hopes of targeted
therapies, neighboring cells within a tumor could differ in
terms of which RTK showed amplification. These types of
studies clearly documented the existence of intra-tumor
genetic heterogeneity and supported the idea that het-
erogeneity might be clinically important.
The work of Gerlinger et al15 on renal cell carcinoma
(RCC) demonstrated the power of NGS to elucidate clinical
implications of intra-tumor genetic heterogeneity. They
sampled and directly sequenced multiple samples from four
RCCs. The authors could thus reconstruct subclonal pro-
gressions of mutations that led to the dramatic differences
they found among separate portions of individual tumors.
Different tumor-suppressor genes could be mutated in
different regions of the same tumor, suggesting convergent
functional evolution. A mutation leading to constitutively
active mTOR was present in some portions of a tumor while
missing from others. Associated CNA analysis also docu-
mented intra-tumor genetic heterogeneity, and a prog-
nostic signature based on mRNA expression of 110 genes
could show either good prognosis or poor prognosis,
depending on the tumor region examined.
These and other studies of intra-tumor heterogeneity
over the past several years16 had clear clinical implications,
particularly for modern targeted therapy. As noted above,
work four decades ago had suggested that resistant sub-
clones within a tumor might account for failure of therapy,
a possibility recognized even in the early days of targeted
therapy.6 Even for therapy targeted against a presumed
driver of all cells of a tumor, if a subclone lacked the tar-
geted mutation or had acquired a different mutation that
conferred resistance, then even a dramatic initial response
to targeted therapy (representing the bulk of the tumor)
could be negated by the outgrowth of persistent disease.
Despite these research advances and their clinical im-
plications, the methods used in these studies were difficult
to translate to clinical practice. Generally applicable
methods like NGS required multiple sampling and multiple
analyses that would not be practical in routine clinical
application. Although techniques like FISH could be used to
evaluate anatomic heterogeneity of defined genomic re-
gions, such methods required pre-identification of genomic
regions of interest. For translation to the clinic, there
needed to be a generally applicable method for evaluating
intra-tumor genetic heterogeneity that could be applied to
the initial tumor biopsy specimen.Mutant-allele tumor heterogeneity (MATH) and
HNSCC
The first reports of large-scale exome NGS in HNSCC17,18
illustrated the lack of attention to intra-tumor genetic
heterogeneity as recently as 5 years ago. They also, how-
ever, provided the information needed to develop a general
way to measure that heterogeneity.
Even as large-scale genomic sequencing of tumors began
about a decade ago, the focus generally remained on what
mutations were identified within a tumor rather than on
whether all cancer cells had the same mutations. Although
the use of NGS rather than Sanger sequencing allowed
analysis of subclonal mutations in a tumor, research inter-
est was primarily on identifying “driver” mutations ac-
counting for transformations of a normal cell into the
cancer cells of a tumor, rather than on “passenger” muta-
tions that had occurred before invasive cancer had devel-
oped or that emerged as a tumor progressed.19 Thus
subclonal mutations were of secondary interest.
Neither of the first two papers on large-scale exome
sequencing of HNSCC, appearing back-to-back in Science in
2011,17,18 noted the possibility of subclonal mutations. Both
simply used the number of mutations found per megabase
of DNA analyzed as a measure of mutation rate, regardless
of the fraction of tumor DNA that contained each mutation.
One of those papers17 did not even provide data on mutant-
allele fraction (MAF) values that might help distinguish
subclonal mutations.
The second paper on HNSCC exome sequencing, how-
ever, provided the information needed to develop a simple,
useful measure of intra-tumor genetic heterogeneity. For
the somatic mutations they identified, Stransky et al18
provided (in supplemental data) the number of DNA
sequence reads that showed the reference DNA sequence
and the number that showed the mutated sequence. We
realized that this might be sufficient to let us assess the
heterogeneity within each tumor.
Ourbasic ideawas simple, illustrated inFig. 1.Wereasoned
that mutations restricted to subclones of a tumor would tend
to appear at lower MAF values than would mutations shared
among all cancer cells of a tumor. Thus tumors with higher
genetic heterogeneity might be expected to have a wider
range of MAF values among their mutated loci than would
tumors with low heterogeneity, even in a single sample of a
tumor. To minimize contributions from loci with MAF values
affected massively by CNA, we used a robust measure of the
width of the distribution, the median absolute deviation.
We also recognized, however, that we would have to
correct for differences among tumor samples in the “im-
purity” of normal cell DNA diluting cancer-cell DNA. We
reasoned that most somatic mutations in a tumor were
likely to be heterozygous “passenger” mutations that had
not undergone selection, and thus should have typical MAF
values on the order of 0.5 among the cancer cells within a
tumor. A lower median MAF value would suggest increasing
“impurity” from normal DNA. Thus normalizing raw MAF
values by the median MAF value among mutated loci for
each tumor should provide a first-order correction for DNA
“impurity,” allowing more reliable comparisons of hetero-
geneity among tumors.
Fig. 1 The idea behind mutant-allele tumor heterogeneity (MATH) measurement. Heterozygous mutations in a tumor in which all
cells share the same mutations (top) will show a narrow distribution of mutant-allele fractions (MAF) after DNA is extracted and
subjected to next-generation sequencing (left to right). The width of the distribution of MAF will represent random sampling of
mutant and normal alleles, as illustrated hypothetically for 100 total reads at each locus (right). Cells whose combination of shared
and unique mutations defines a genetically heterogeneous tumor (bottom) will show a wider distribution of MAF values and a lower
median MAF value among mutated loci. MATH is the percentage ratio of the distribution width (the median absolute deviation,
MAD) to the median MAF value. Adapted from Mroz and Rocco,20 with permission.
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of MAF values as a percentage of the tumor’s median MAF
value. We called the resulting measure “mutant-allele
tumor heterogeneity” (MATH).
From the limited clinical data initially provided for 74
HNSCC cases by Stransky et al,18 we quickly realized that
MATH was associated with poor-prognosis characteristics of
HNSCC, as might be expected of a useful measure of intra-
tumor genetic heterogeneity (Fig. 2). MATH was lower in
tumors positive for human papillomavirus (HPV), with their
typically better clinical outcomes, than in HPV-negative
tumors, even if the HPV-negative tumors had wild-type
TP53. MATH was higher in tumors that bore dis-
ruptiveTP53 mutations, with their reportedly worse clinical
outcomes,21 than in tumors with wild-type TP53 or with
non-disruptive mutations. In the Stransky et al18 cases,
MATH increased with pack-years of smoking, a known poor
prognostic marker, when TP53 mutation status was taken
into account. Thus this very simple measure of heteroge-
neity, which could be obtained from a single sample of a
tumor, showed considerable promise from the outset.20
Notably, MATH values represented something other than
simply the mutation rates within the tumors. To the initial
surprise of some colleagues, who thought that MATH might
simply represent mutation rate, the MATH value was inde-
pendent of the number of mutations within a tumor (Fig. 3),
which is proportional to the usual measure of mutation rate
in exome-sequencing studies (mutations per megabase oftargeted genomic DNA). MATH evidently was capturing, as
intended, differences of mutations among cancer cells of a
tumor.High tumor MATH values and shorter overall
survival in HNSCC
These promising initial findings prompted us to test
whether tumor MATH values were related to individual
clinical outcomes, not just to poor-outcome classes of
HNSCC. We worked with colleagues who had been involved
in the Stransky et al18 study to obtain and analyze more
detailed clinical data for those patients, including overall
survival.
Increasing MATH was significantly related to shorter
overall survival among those 74 patients, both as an indi-
vidual variable and when other prognostic variables were
taken into account.22 For plotting survival curves we chose
a MATH cutoff of 32, equal to the median of these 74 tumor
MATH values. On that basis, patients with high-MATH tu-
mors had twice the hazard of death as those with low-MATH
tumors (Fig. 4). For those who received systemic chemo-
therapy the high/low-MATH hazard ratio of 4 was even
larger (Fig. 5).
In order to generalize this finding of a relation of MATH
to outcome, we needed to validate the finding in an in-
dependent data set. The Stransky et al18 data came from a
Fig. 2 Relation of MATH values to HPV status and TP53 mutation status in HNSCC. Box-and-whisker plots with individual tumor
MATH values shown for HNSCC sequenced by Stransky et al.18 Adapted from Mroz and Rocco,20 with permission.
Fig. 3 MATH values of HNSCC are not closely related to the
number of mutations, a standard measure of mutation rate.
Shown for HNSCC sequenced by Stransky et al.18 From Mroz and
Rocco,20 used with permission.
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relatively limited in numbers (74 patients, 39 deaths) even
though at the time it was the largest single group of
HNSCC patients whose tumors had been subjected to
exome NGS.
The Cancer Genome Atlas (TCGA) provided such an in-
dependent data set. This multi-institutional, internationalFig. 4 Relation of MATH to overall survival in the 74 patients
whose HNSCC had been sequenced by Stransky et al.18
KaplaneMeier curves from Mroz et al,22 used with permission.
Fig. 5 Relation of MATH to overall survival in patients whose
HNSCC had been sequenced by Stransky et al18 and who had
received systemic chemotherapy as part of treatment.
KaplaneMeier curves from Mroz et al,22 used with permission.
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Health set out to obtain detailed molecular information,
including tumor-specific genomic mutations, for hundreds
of tumors from each of more than 20 types of cancer, along
with corresponding patient clinical data.23 Molecular and
clinical data on HNSCC were available to the public even
before the initial publication of molecular analyses by
TCGA.24
We were careful to treat these TCGA data as a validation
data set for our initial findings on MATH and outcome. As
the Stransky et al18 data included no MAF values below
0.075, we restricted MATH calculations in the TCGA data to
genomic loci with MAF values at or above that cutoff, and
used identical methods for calculating MATH values. When
distinguishing high-heterogeneity from low-heterogeneity
tumors, we also used the identical MATH value cutoff of
32, rather than optimize to the TCGA data set.
With these TCGA data on HNSCC we thus established a
relation of high intra-tumor heterogeneity to worse
outcome in a large, multi-institutional study, for the first
time to our knowledge in any type of cancer.25 We validated
both the overall relation of MATH to HNSCC outcome and a
particularly strong relation among patients who received
chemoradiation. With this larger data set (305 patients, 131
deaths) we also could demonstrate that high MATH was
related to worse outcome even when HPV and TP53 muta-
tion status, tumor grade, smoking history, T and N classifi-
cations, age, gender, and TNM stage were taken into
account in a multi-variable survival model. Within both
oral-cavity and laryngeal subsites, MATH values significantly
distinguished outcome classes within TNM stage classes
(Fig. 6). Although these data were not obtained from a
prospectively designed study, the combination of cases
from multiple institutions provided a patient population
that was reasonably representative of surgically treated
patients in the US having stage II, III, and IV HNSCC. Thus
there is very strong evidence that high intra-tumor genetic
heterogeneity is associated with worse clinical outcome in
HNSCC. The predictions of clinical significance of intra-
tumor heterogeneity based on pioneering basic sciencestudies nearly 4 decades ago have been validated, at least
for HNSCC.What MATH is measuring
The explanation above focused on genetically distinct
subclones within a tumor as the justification for the MATH
algorithm and for a relation of high MATH to worse
outcome. Nevertheless, in our first report we noted that
the MATH algorithm might represent additional phenomena
contributing to worse outcome.20 In particular, the MATH
algorithm for identifying intra-tumor heterogeneity would
pick up diversity in MAF values among mutated loci arising
not only from subclones but also from a diversity of CNA
values among genomic loci, even in a monoclonal tumor. It
also could pick up the type of “pseudodiploid” CNA, not
necessarily associated with defined subclones, reported in
breast cancer by Navin et al.13
There is some evidence that CNA makes an important
contribution to tumor MATH values and their relation to
outcome. A pan-cancer analysis of TCGA tumors identified
two major classes of tumors based on patterns of genomic
alterations. One, class M, was predominantly characterized
by somatic point mutations while the other, class C, showed
high levels of CNA instead.26 Many of the TCGA HNSCC had
been classified in that paper, so we evaluated the relations
of these tumor classes to MATH and to outcome. Class C
tumors, with high CNA, showed significantly higher MATH
values than did class M tumors, and class C tumors were
associated with shorter overall survival (although the as-
sociation of class C with outcome lost significance when
MATH and HPV status were taken into account).25 So a
contribution of CNA both to high MATH values and to worse
outcome seems likely.
Whether MATH is primarily measuring diversity of point
mutations or of CNA, it evidently is capturing some aspect
of a tumor that is related to worse outcome. The idea that
MATH is measuring tumor subclones that may have pre-
existing resistance to systemic therapy, as suggested 40
years ago as an explanation for therapy resistance, is only
one way that high MATH scores might be related to poor
outcome. Another possibility is that MATH provides a
measure of the evolutionary age of the tumor, with an older
tumor more likely to have developed an occult metastasis
at time of presentation. Consistent with that possibility,
patients with high-heterogeneity HNSCC were more likely
to show spread of disease to loco-regional nodes.25 Alter-
natively, high MATH might represent a potential to develop
non-lethal point mutations or CNA continually, consistent
with the “mutator phenotype” proposed by Loeb.27 In that
circumstance, cytotoxic therapy might lead to the
appearance and selection of resistance mutations even if
they were not present prior to therapy.
As these different processes may have different thera-
peutic implications it is crucial to learn which are at work.
To understand better what MATH is capturing at a cellular
and molecular level, we are working with colleagues who
have developed methods for teasing out the contributions
of normal DNA, overall changes in DNA ploidy, more local-
ized CNA, and subclonal somatic point mutations to the
observed MAF values in a tumor.28
Fig. 6 MATH values (low, blue; high, red) distinguish outcomes in patients with oral-cavity (left) or laryngeal (right) tumors (top),
even when TNM stage is taken into account (bottom). KaplaneMeier of cases analyzed by The Cancer Genome Atlas. From Mroz
et al,25 figure freely available under the Creative Commons Attribution license.
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genetic heterogeneity
Routine clinical application of intra-tumor heterogeneity
assessment must await validation of relations between
heterogeneity and outcome in samples from prospectively
designed clinical studies. Nevertheless, given the compelling
evidence from many types of cancer of the clinical impor-
tance of intra-tumor heterogeneity, beginning the discussion
about its clinical implications is clearly warranted now.
As noted above, one most obvious implication of intra-
tumor heterogeneity is the limit that it may place on
modern “targeted” therapy. The idea that a tumor is driven
by a particular deranged cellular signaling pathway or even
is “addicted to” a particular mutation in such a pathway
formed the basis for developing drugs that target such
pathways or mutations. Even if the target itself is a founder
event and is present in all cancer cells of a tumor, intra-
tumor heterogeneity may mean that some subclone of cells
already harbors additional mutations that will prevent cell
death when the target is inhibited. Heterogeneity could
even mean that the target was lost from a subclone in later
stages of tumor development, as mutations in other pro-
teins replaced its originally necessary function. Either
explanation is certainly consistent with typical clinical re-
sponses of tumors to targeted therapy, where initial dra-
matic reductions in tumor volume are typically followed byrelapse in a few months. At the least, trials of targeted
therapies might best be stratified by intra-tumor hetero-
geneity to evaluate these possibilities.
A second implication is that measurement of intra-tumor
heterogeneity may help inform treatment choices, not just
provide prognostic information. Results to date in HNSCC
suggest that the relation of MATH to outcome may be most
striking when standard systemic therapy is part of initial
treatment,22,25 consistent either with selection of pre-
existing resistance mutations or with a tendency to
develop mutations that may lead to resistance in high-
heterogeneity tumors. If MATH is highly related to sys-
temic therapy outcome but not so strongly to surgical
outcome, high-heterogeneity tumors might preferentially
be treated with surgery if there is a choice.
This implication of intra-tumor heterogeneity may be
particularly important in HNSCC, in which there often is a
choice between surgical and organ-preserving cytotoxic
therapies for primary treatment. With recent advances in
surgical technologies, both surgery and organ-preserving
chemoradiation can be considered even for previously
poorly accessible anatomic sites like the oropharynx.29 If
future studies show that high intra-tumor genetic hetero-
geneity is strongly related to poor outcome following che-
moradiation but not following surgical therapy, then
assessment of heterogeneity may help inform this funda-
mental treatment choice. Similarly, the relation of high
Intra-tumor heterogeneity 67primary tumor heterogeneity to nodal metastasis noted
above might help inform the choice of whether to perform
a neck dissection in oral-cavity cancer in the clinical N0
setting.
A third implication is that the processes that lead to high
heterogeneity might themselves represent novel targets for
therapy. An analogy can be drawn to mutational variation in
microorganisms: too little genetic diversity and the popu-
lation may be at risk of a novel environmental threat, too
much diversity and genetic catastrophe results. The popu-
lation of cancer cells may similarly be balanced between
homogeneity and excess diversity.30 If the processes that
lead to that balance can be identified, it might be possible
to drive the balance either way to favor destruction of
cancer cells.
Intra-tumor genetic heterogeneity has now been docu-
mented in many types of cancer, and a large-scale associ-
ation of intra-tumor genetic heterogeneity and cancer
outcome as been established in HNSCC. It is thus time to
consider intra-tumor heterogeneity and its implications
explicitly as translational research and clinical practice
progress.
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